Journal
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
Volume 21, Issue 4, Pages 763-770Publisher
BMJ PUBLISHING GROUP
DOI: 10.1097/IGC.0b013e31821b2669
Keywords
Molecular agents; Ovarian cancer; Clinical trials
Categories
Funding
- Astra Zeneca
- Roche
- GlaxoSmithKline
- Pharmamar
- Ortho Biotech
- Boehringer Ingelheim
- Canadian Cancer Society Research Institute
- Ovarian Cancer Canada
- National Cancer Institute (US)
- Taiho
- Merck
- Pfizer
- Amgen
- MRC [G0601891] Funding Source: UKRI
- Medical Research Council [G0601891] Funding Source: researchfish
Ask authors/readers for more resources
There is now a greater understanding of the molecular pathways in ovarian cancer, and using this knowledge, a large number of new therapeutic agents can be tested. The success of these drugs will depend on selecting drugs that target known key dysfunctional molecular pathways. To make best use of these compounds, prognostic and predictive biomarkers need to be identified. Novel methods of assessment such as functional imaging need to be developed as additional biological end points to evaluate these therapies. Promising antitumor activity has been observed with some drugs, and careful consideration is needed to determine in what circumstances new agents, such as anti-angiogenic compounds, could be considered as a standard therapy. These areas were discussed at the 4th Ovarian Cancer Consensus Conference.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available